Immunovant, Inc.

IMVTSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1764013

Concept	FY2025	FY2024	FY2023	FY2022	FY2020
Research and Development Expense	—	—	—	$68.6M	$47.9M
Operating Expenses	$218.3M	$218.3M	$156.0M	$108.1M	$66.1M
Interest Expense	—	—	—	—	$625.0K
Other Nonoperating Income (Expense)	-$253.0K	-$253.0K	-$781.0K	$328.0K	$412.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$211.0M	-$211.0M	-$156.8M	-$107.8M	—
Income Tax Expense (Benefit)	$9.0K	$9.0K	-$84.0K	-$358.0K	$97.0K
Net Income (Loss) Attributable to Parent	-$211.0M	-$211.0M	-$156.7M	-$107.4M	-$66.4M
Earnings Per Share, Basic	-$1.71	-$1.71	-$1.43	-$1.22	—
Earnings Per Share, Diluted	-$1.71	-$1.71	-$1.43	-$1.22	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2020
Assets	$666.4M	$405.8M	$515.6M	$412.5M	$109.4M
Assets, Current	$665.8M	$404.3M	$512.9M	$409.0M	$109.1M
Cash and Cash Equivalents, at Carrying Value	$635.4M	$376.5M	$493.8M	$400.1M	$100.6M
Accounts Receivable, after Allowance for Credit Loss, Current	$5.3M	$700.0K	$12.2M	$596.0K	—
Liabilities	$48.6M	$43.3M	$45.7M	$21.0M	$15.3M
Liabilities, Current	$48.6M	$43.3M	$44.5M	$18.8M	$15.3M
Accounts Payable, Current	$7.2M	$1.4M	$18.6M	$2.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2020
Net Cash Provided by (Used in) Operating Activities	-$188.2M	-$188.2M	-$106.1M	-$83.3M	-$53.4M
Net Cash Provided by (Used in) Investing Activities	-$197.0K	-$197.0K	-$254.0K	-$210.0K	-$31.0K
Net Cash Provided by (Used in) Financing Activities	$70.9M	$70.9M	$200.1M	$383.1M	$147.0M
Payments to Acquire Property, Plant, and Equipment	$197.0K	$197.0K	$254.0K	$210.0K	$31.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)